Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Diabetes mellitus is a common chronic disease.

Dyslipidemia and hypertension are two complications that may develop in diabetic patients if hyperglycemia, insulin resistance, and weight gain are not controlled.

Who Took Part

According to the abstract, 50 patients were involved.

Systolic blood pressure (SBP), mean arterial pressure (MAP), pulse pressure (PP), the atherogenic index of plasma (AIP), weight, body mass index (BMI), waist and hip circumference (WC, HC), a body shape index (ABSI), abdominal volume index (AVI), body adiposity index (BAI), lipid accumulation product (LAP), conicity index, and waist-to-height ratio (WHtR) were evaluated in all the patients pre- and post-intervention.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Copper (Supplement), giving a reference point.

What Was Measured

The subject headings attached to it are Body Mass Index, Cardiovascular Diseases, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Dietary Supplements, Iran and Melatonin.

The authors tagged it with the keywords Blood pressure, New anthropometric indices and Type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 50 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Trials), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.